BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trad D, Bibani N, Sabbah M, Elloumi H, Gargouri D, Ouakaa A, Kharrat J. Known, new and emerging risk factors of hepatocellular carcinoma (review). La Presse Médicale 2017;46:1000-7. [DOI: 10.1016/j.lpm.2017.09.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Cheng W, Zheng S, Li L, Zhou Q, Zhu H, Hu J, Luo H. Chloride channel 3 (CIC-3) predicts the tumor size in hepatocarcinoma. Acta Histochemica 2019;121:284-8. [DOI: 10.1016/j.acthis.2019.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Nandhini JT, Ezhilarasan D, Rajeshkumar S. An ecofriendly synthesized gold nanoparticles induces cytotoxicity via apoptosis in HepG2 cells. Environmental Toxicology 2021;36:24-32. [DOI: 10.1002/tox.23007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang S, Ma H, Li X, Mo X, Zhang H, Yang L, Deng Y, Yan Y, Yang G, Liu X, Sun H. DNASE1L3 as an indicator of favorable survival in hepatocellular carcinoma patients following resection. Aging (Albany NY) 2020;12:1171-85. [PMID: 31977318 DOI: 10.18632/aging.102675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Malov SI, Malov IV, Dvornichenko VV, Rasulov RI, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, Yushchuk ND. [Application of alpha-fetoprotein and osteopontin combination for early diagnosis of hepatocellular carcinoma associated with hepatitis C.]. Klin Lab Diagn 2019;64:607-12. [PMID: 31742954 DOI: 10.18821/0869-2084-2019-64-10-607-612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Demers AA, Brenner DR, Smith L, Shaw A. At-a-glance - Cancer trends in Canada, 1984 to 2015. Health Promot Chronic Dis Prev Can 2019;39:310-4. [PMID: 31729314 DOI: 10.24095/hpcdp.39.11.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han K, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. Journal of Hepatology 2019;71:456-64. [DOI: 10.1016/j.jhep.2019.03.028] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 23.0] [Reference Citation Analysis]
7 Lin CH, Hsieh MJ, Lee HL, Yang SF, Su SC, Lee WJ, Chou YE. Effects of MACC1 polymorphisms on hepatocellular carcinoma development and clinical characteristics. J Cancer 2020;11:1641-7. [PMID: 32047570 DOI: 10.7150/jca.38856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022;1:CD013345. [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2] [Reference Citation Analysis]
9 Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, Ni Y. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers (Basel) 2019;11:E1782. [PMID: 31766180 DOI: 10.3390/cancers11111782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]